lateonset.next {CFO} | R Documentation |
Determination of the dose level for next cohort in the calibration-free odds type (CFO-type) design with late-onset toxicity
Description
The function is used to determine the next dose level in the CFO-type design with late-onset toxicity, specifically, including time-to-event CFO (TITE-CFO) design, fractional CFO (fCFO) design, benchmark CFO design, time-to-event accumulative CFO (TITE-aCFO) design, fractional accumulative CFO (f-aCFO) design and benchmark aCFO design.
Usage
lateonset.next(design, target, p.true, currdose, assess.window, enter.times, dlt.times,
current.t, doses, prior.para = list(alp.prior = target, bet.prior = 1 - target),
cutoff.eli = 0.95, early.stop = 0.95)
Arguments
design |
option for selecting different designs, which can be set as |
target |
the target DLT rate. |
p.true |
the true DLT rates under the different dose levels. |
currdose |
the current dose level. |
assess.window |
the maximal assessment window size. |
enter.times |
the time that each participant enters the trial. |
dlt.times |
the time to DLT for each subject in the trial. If no DLT occurs for a subject,
|
current.t |
the current time. |
doses |
the dose level for each subject in the trial. |
prior.para |
the prior parameters for a beta distribution, where set as |
cutoff.eli |
the cutoff to eliminate overly toxic doses for safety. We recommend
the default value of |
early.stop |
the threshold value for early stopping. The default value |
Details
Late-onset outcomes commonly occur in phase I trials involving targeted agents or immunotherapies. The TITE
framework and fractional framework serve as two imputation methods to handle pending data
related to late-onset outcomes. This approach extends the CFO and aCFO designs to integrate time information
for delayed outcomes, leading to the development of TITE-CFO, fCFO, TITE-aCFO, and f-aCFO designs.
In the TITE framework context, an assumption about the distribution of time to DLT must be pre-specified,
whereas the fractional framework does not require justification for a specific distribution of the time to
DLT. Consequently, fCFO and f-aCFO adapt to a more diverse range of scenarios.
The function lateonset.next()
also provides the option to execute
the benchmark CFO and benchmark aCFO design. These two methods await complete observation of toxicity outcomes for
the previous cohorts before determining the next dose assignment. This enhances precision but comes at the
expense of a prolonged trial duration.
Value
The lateonset.next()
function returns
target: the target DLT rate.
decision: the decision in the CFO design, where
left
,stay
, andright
represent the movement directions, andstop
indicates stopping the experiment.currdose: the current dose level.
nextdose: the recommended dose level for the next cohort.
overtox: the situation regarding which position experiences over-toxicity. The dose level indicated by
overtox
and all the dose levels above experience over-toxicity.overtox = NA
signifies that the occurrence of over-toxicity did not happen.over.doses: a vector indicating whether the dose level (from the first to last dose level) is over-toxic or not (1 for yes).
toxprob: the expected toxicity probability,
Pr(p_k > \phi | x_k, m_k)
, at all dose levels, wherep_k
,x_k
, andm_k
is the dose-limiting toxicity (DLT) rate, the numbers of observed DLTs, and the numbers of patients at dose levelk
.
Author(s)
Jialu Fang, Wenliang Wang, and Guosheng Yin
References
Jin H, Yin G (2022). CFO: Calibration-free odds design for phase I/II clinical trials.
Statistical Methods in Medical Research, 31(6), 1051-1066.
Jin H, Yin G (2023). Time‐to‐event calibration‐free odds design: A robust efficient design for
phase I trials with late‐onset outcomes. Pharmaceutical Statistics, 22(5), 773–783.
Yin G, Zheng S, Xu J (2013). Fractional dose-finding methods with late-onset toxicity in
phase I clinical trials. Journal of Biopharmaceutical Statistics, 23(4), 856-870.
Fang J, Yin G (2024). Fractional accumulative calibration‐free odds (f‐aCFO) design for delayed toxicity
in phase I clinical trials. Statistics in Medicine.
Examples
target <- 0.2; p.true <- c(0.01, 0.07, 0.20, 0.35, 0.50, 0.65, 0.80)
enter.times<- c(0, 0.266, 0.638, 1.54, 2.48, 3.14, 3.32, 4.01, 4.39, 5.38, 5.76,
6.54, 6.66, 6.93, 7.32, 7.66, 8.14, 8.74)
dlt.times<- c(0, 0, 0, 0, 0, 0, 0, 0, 0, 0.610, 0, 2.98, 0, 0, 1.95, 0, 0, 1.48)
current.t<- 9.41
doses<-c(1, 1, 1, 2, 2, 2, 3, 3, 3, 4, 4, 4, 3, 3, 3, 4, 4, 4)
## determine the dose level for the next cohort using the TITE-CFO design
decision <- lateonset.next(design = 'TITE-CFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)
## determine the dose level for the next cohort using the TITE-aCFO design
decision <- lateonset.next(design = 'TITE-aCFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)
## determine the dose level for the next cohort using the f-CFO design
decision <- lateonset.next(design = 'fCFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)
## determine the dose level for the next cohort using the f-aCFO design
decision <- lateonset.next(design = 'f-aCFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)
## determine the dose level for the next cohort using the benchmark CFO design
decision <- lateonset.next(design = 'bCFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)
## determine the dose level for the next cohort using the benchmark aCFO design
decision <- lateonset.next(design='b-aCFO', target, p.true, currdose = 4, assess.window = 3,
enter.times, dlt.times, current.t, doses)
summary(decision)